ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...

Add Yahoo as a preferred source to see more of our stories on Google. A subset of FreeStyle Libre 3 plus sensors may provide incorrect low glucose reading, Health Canada says. (Brian Morris/CBC - ...

Medical device giant Abbott announced on Sunday that it is recalling approximately 3 million glucose monitoring sensors after discovering they could give dangerously inaccurate low blood sugar ...

Thursday, Abbott Laboratories (NYSE:ABT) said it is recalling some FreeStyle Libre 3 sensors after finding that a small number of FreeStyle Libre 3 sensors may provide incorrect high glucose readings.

"Sensor-based glucose monitoring has transformed diabetes care," said Akshay Jain, M.D., a nationally recognized endocrinologist based in Surrey, British Columbia. "These intuitive tools, like the ...

Tandem Diabetes Care begins global commercial rollout of t:slim X2 pump integration with the FreeStyle Libre 3 Plus CGM sensor, expanding choice and personalization for people living with diabetes ...

ABBOTT PARK, Ill., July 24, 2024 – Abbott has initiated a voluntary medical device correction for a small number of FreeStyle Libre® 3 sensors distributed in the United States during the first half of ...

Abbott Laboratories announced a recall of Freestyle Libre 3 and Libre 3 Plus sensors used in continuous glucose monitors after receiving reports of more than 700 injuries and seven fatalities that may ...

Coverage means more Canadians with diabetes can access Abbott's sensor-based glucose technology, giving them actionable insights to manage their condition confidently, i "Sensor-based glucose ...

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ ...